<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97363">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01796457</url>
  </required_header>
  <id_info>
    <org_study_id>DK082864 Immunology Treatment</org_study_id>
    <secondary_id>U01DK082864</secondary_id>
    <nct_id>NCT01796457</nct_id>
  </id_info>
  <brief_title>HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B</brief_title>
  <official_title>HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an ancillary to the NIDDK-sponsored treatment trials titled: Combination Therapy of
      Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis
      B (NCT01369212) and Combination Entecavir and Peginterferon Therapy in HBeAg-Positive
      Immune-Tolerant Adults With Chronic Hepatitis B (NCT01369199).

      This study will examine the balance between immune regulatory and effector responses in
      hepatitis B-infected participants enrolled in the HBRN's clinical trials (NCT01369212 and
      NCT01369199) to define natural history and treatment outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1. Therapeutic HBV suppression will enhance antiviral immune effector responses and
      reduce immune inhibitory factors in participants with chronic hepatitis B. This study will
      also examine if antiviral therapy has a durable effect in host immune phenotype and define
      the immunological effect of interferon-alpha (IFNÎ±) therapy in chronic HBV participants.

      Aim 2. Antiviral immune effector and regulatory responses before, during and/or after
      therapy can predict long term therapeutic response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Immune regulatory and effector responses relative to HBV DNA, ALT and clinical outcome</measure>
    <time_frame>up to 192 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>HBV-specific lymphoproliferative, IFN-gamma and IL10 responses, T cell activation and costimulatory markers ( PD1, CTLA4, CD28, CD127), FoxP3+ Treg frequency, and NK frequency and expression of activating/inhibitory receptors Dendritic cell frequency</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Hepatitis B</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be recruited from multi-site clinical centers in the United
        States and Canada including primary care hospitals and community centers that have
        enrolled into the HBRN clinical trials (NCT01369212 or NCT01369199).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -

        Exclusion Criteria:

          -  Children under 18 years of age, participants with anemia

          -  Anemia with Hgb&lt;10 or Hct&lt;30 and active medical conditions such as congestive heart
             failure or chronic lung disease requiring oxygen, active coronary artery disease with
             unstable angina, sepsis and renal failure

          -  Participants with significant medical conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyong-Mi Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Valiga, RN</last_name>
    <phone>215-823-5800 Ext. 6726</phone>
    <email>mevaliga@mail.med.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stewart Cooper, MD</last_name>
      <phone>415-600-1548</phone>
      <email>scooper@cpmcri.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norah Terrault, MD,MPH</last_name>
      <phone>415-476-2227</phone>
      <email>norah.terrault@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daryl Lau, MD</last_name>
      <phone>617-632-1098</phone>
      <email>dlau@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ray Chung, MD</last_name>
      <phone>617-724-7562</phone>
      <email>rtchung@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Coleman Smith, MD</last_name>
      <phone>612-871-1145</phone>
      <phone_ext>2908</phone_ext>
      <email>smith146@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim W. Ray, MD</last_name>
      <phone>507-538-0254</phone>
      <email>kim.woong@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Lee, MD</last_name>
      <phone>214-645-6110</phone>
      <email>william.lee@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Sterling, MD</last_name>
      <phone>804-828-4060</phone>
      <email>rksterli@vcu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Carithers, MD</last_name>
      <phone>206-598-4956</phone>
      <email>robertc@medicine.washington.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kris Kowdley, MD</last_name>
      <phone>206-223-2319</phone>
      <email>kkowdley@benaroyaresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital Liver Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jenny Heathcote, MD</last_name>
      <phone>416-603-5914</phone>
      <email>jenny.heathcote@utoronto.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.hepbnet.org</url>
    <description>Hepatitis B Research Network (HBRN) Website</description>
  </link>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>June 21, 2013</lastchanged_date>
  <firstreceived_date>February 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Immunology</keyword>
  <keyword>HBV</keyword>
  <keyword>Immune tolerant</keyword>
  <keyword>Immune active</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
